Report : Middle East & Africa Manufacturing Execution System (MES) In Life Sciences Market Forecast to 2033–COVID-19 Impact and Regional Analysis– by Offering (Software and Services), Deployment (On-Premises and Cloud), Organization Size (SMEs and Large Enterprises), and Application (Pharmaceutical, Biotechnology, and Medical Devices)
At 10.2% CAGR, the Middle East & Africa Manufacturing Execution System (MES) In Life Sciences Market is speculated to be worth US$ 609.93 million by 2033, says Business Market Insights
According to Business Market Insights research, the Middle East & Africa manufacturing execution system in life sciences market was valued at US$ 231.17 million in 2023 and is expected to reach US$ 609.93 million by 2033, registering a CAGR of 10.2% from 2023 to 2033. Need for compliances with regulatory framework and requirement of accurate real-time data in production management process are the critical factors attributed to the Middle East & Africa manufacturing execution system in life sciences market expansion.
Manufacturing execution systems (MES) are solutions that aid pharmaceutical and medical device manufacturers to easily comply with such regulations while capturing details on each step of the manufacturing process. The FDA requires every medical device manufacturer to maintain Design History File (DHF) and Device History Records (DHR) to ensure that DHRs for each batch, lot, or unit can further help demonstrate that the device is manufactured as per the Device Master Record (DMR) and the requirements of this devices. DHR includes all the details pertinent to manufacturing a medical device, while DHF demonstrates the history of how the product was designed. The data was traditionally recorded on paper, which consisted of production travelers and other documentation. However, these paper-oriented processes expose companies to unnecessary risks, including in-process deviations and non-conformances, which can lead to product quality issues in the field. Modern MES have built-in features that enforce production processes and capture information associated with production records. In addition, pharmaceutical companies are also adopting Electronic Batch Manufacturing Record (eBMR) in place of paper-based Batch Manufacturing Record (BMR). eBMR can help them comply with global regulatory norms, quality processes, and ALCOA+ norms. ALCOA+ is a set of principles that ensures data integrity in the life sciences sector and is crucial for complying with Good Manufacturing Practices (GMP). Such integrations of features into the MES that ensure compliance with the regulatory framework boost the demand for MES in the pharmaceutical & medical device manufacturing industry.
On the contrary, high cost and lack of flexibility hampers the Middle East & Africa Manufacturing Execution System (MES) In Life Sciences Market .
Based on offering, the Middle East & Africa manufacturing execution system in life sciences market is segmented into software and services. The services segment held 69.6% share of Middle East & Africa Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 160.85 million. It is projected to garner US$ 435.50 million by 2033 to expand at 10.5% CAGR during 2023–2033.
Based on deployment, the Middle East & Africa manufacturing execution system in life sciences market is segmented into on-premises and cloud. The on-premises segment held 61.2% share of Middle East & Africa Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 141.56 million. It is projected to garner US$ 315.38 million by 2033 to expand at 8.3% CAGR during 2023–2033.
Based on organization size, the Middle East & Africa manufacturing execution system in life sciences market is segmented into SMEs and large enterprises. The large enterprises segment held 83.6% share of Middle East & Africa Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 193.23 million. It is projected to garner US$ 500.50 million by 2033 to expand at 10.0% CAGR during 2023–2033.
Based on application, the Middle East & Africa manufacturing execution system in life sciences market is segmented into pharmaceutical, biotechnology, and medical devices. The pharmaceutical segment held 53.7% share of Middle East & Africa Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 124.09 million. It is projected to garner US$ 311.91 million by 2033 to expand at 9.7% CAGR during 2023–2033.
Based on country, the Middle East & Africa manufacturing execution system in life sciences market has been categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that the UAE captured 29.5% share of Middle East & Africa Manufacturing Execution System (MES) In Life Sciences Market in 2023. It was assessed at US$ 68.08 million in 2023 and is likely to hit US$ 195.48 million by 2033, exhibiting a CAGR of 11.1% during the forecast period.
Key players dominating the Middle East & Africa manufacturing execution system in life sciences market are ATS Global B.V.; Emerson Electric Co; Rockwell Automation Inc; Schneider Electric SE; and Siemens AG, among others.
- Jan 2023, Autolomous LTD—a developer of critical manufacturing management systems for Cell and Gene Therapies (CGT)—announced a license agreement with US-based Center for Breakthrough Medicines (CBM), a cell and gene therapy contract development, manufacturing, and testing organization (CDMO). The agreement allowed Autolomous to design, configure and integrate solutions for CBM utilizing the AutoloMATE platform. It is a business-critical robust digital system, providing CBM with seamless digital connectivity in the manufacturing operations across all critical elements (e.g., facility systems, technologies) for the end-to-end cell and gene therapy (CGT) value chain.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com